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The right therapy for the right patient at the right time is
the most important approach for the provision of proper
health care. The field of rare diseases is an excellent exam-
ple, with patients taking a more central role in the discov-
ery and development of treatments for their disease.
Limited budgets coupled with high failure rates of medi-
cine development lead us to public-private partnerships as
a model to move forward and reduce cost; no stakeholder
alone has all knowledge and expertise.
The newly founded BioPontis Alliance Rare Disease
Foundation presents a scientific and economic partner-
ship model designed to unleash the potential to find
cures for rare (pediatric) diseases. The non-profit Foun-
dation has developed an innovation joint venture busi-
ness and scientific development structure to fill the gap
between discovery science and the biomedical industry.
The Foundation will establish scientific bridges across
the discovery/preclinical development gap as a partner
to independent academic and/or patient organizations
to develop medicine candidates. The BioPontis Alliance
Rare Disease Foundation intends to also establish a
financial bridge between the cures ‘push’ of philanthro-
pic resources and the commercial ‘pull’ of private sector.
The Foundation will provide a professional drug dis-
covery operation in which the necessary scientific exper-
tise for each product/discovery initiative can be selected
and applied to each program. It has a virtual network of
contract research companies and academic institutes
where development work can be conducted as well as
bringing central project management and industry
experienced managers to each initiative. With novel
licensing practices, the Foundation financially honors the
seeding contributions of originating scientists, their host
institutions and/or the Patient organization partner.
Licensing agreements have already been signed with over
12 leading US academic institutions/hospitals, offering
the originators a pro rata share of revenues that are gen-
erated from the full intellectual property estate, thus
removing many of the misalignments of interests in tradi-
tional licensing and sponsored research agreements.
Focus on a single goal of creating potential treatments
for patients is therefore assured across the BARD Foun-
dation’s model.
The BARD Foundation is currently setting up financing
and is seeking donations for its operations. While operating
for a global patient community and market, we seek con-
tacts with potential financial, scientific and patient organi-
zation partners in Europe and other parts of the world.
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